Navigation Links
Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
Date:6/26/2009

l of which is expected mid July 2009.

The Board of Directors will propose to the EGM to conduct a subsequent offering of up to 650,000 new shares (corresponding to 6% of the Private Placement) at NOK 12.00 per share directed towards shareholders in Clavis Pharma as of 25 June 2009 (as documented by the shareholder register in the VPS as of 30 June 2009) that were not allocated new shares in the Private Placement. Consequently, the shares in the Company will trade excluding the right to participate in the subsequent offering from today, 26 June 2009.

For further information on the proposed resolutions to be passed by the EGM, reference is made to a separate announcement to be issued by Clavis Pharma.

About Clavis Pharma

Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid Vector Technology (LVT) platform to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties, greater tissue penetration and, in many cases, additional modes of action.

Clavis Pharma's objective is to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes four new cancer drugs: Elacytarabine is in Clinical Phase II, Intravenous CP-4126 is in Clinical Phase I, Oral CP-4126 in Phase I, and CP-4200 is in early preclinical development. Results indicate that these products have promisi
'/>"/>

SOURCE Clavis Pharma ASA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...mbassador to Speak at Economic Club of Canada , ...ember 25, 2009 -- Ambassador to Speak at Economic ... Ambassador for International Investment, and Chai...ew a biography of David Appia go to www.investinf...able to meet with press to discuss recent pro-busi...
(Date:11/25/2009)...v. 25 /PRNewswire/ - Cytochroma today announced th...Directors. Dr. Moldt will replace Mr. Ulrik Spork ...ard. The number of Board members remains unchanged...come Peter Moldt to the board and look forward to ...ochroma continues to make progress in becoming a l...
(Date:11/25/2009)... Nov. 25 Reportlinker.com announce...n its catalogue: ,, Brazil Bioethanol Market A...eportlinker.com/p0165503/Brazil-Bioethanol-Market-...Bioethanol Market Analysis and Forecasts to 2013 ,...analysis and forecasts of the global bioethanol ma...
(Date:11/24/2009)...e in German . , Whether it,s CD packaging, ...io Frequency Identification) are increasingly find...sible to label objects or goods and identify them ...scanner can read and process the data contained in...nder production conditions of up to 100 degrees Ce...
Breaking Biology Technology:French Ambassador for International Investment to Visit Toronto December 11 2Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10Intelligence inside metal components 2
...rporation (NYSE: EW ), a world leader in products... disease, will host its Annual Meeting of,Stockhol....m. PT (1:00 pm,ET) at the corporate headquarters ...ting will be available to all interested,parties o...site at, http://www.edwards.com/InvestorRelations/...
...c. (Nasdaq: RNVS ) announced today that its stock...ent with Evotec AG (Frankfurt Stock Exchange:,EVT)...The merger is,expected to close by May 5, 2008., ...are of Renovis common,stock will be automatically ...merican Depositary Share (ADSs) of Evotec, with ea...
...tic Life Sciences Inc.,("ProMetic") (TSX:PLI) will...rs on Wednesday, May 7, 2008 at 10:30 a.m. (EDT). ...eeting") will be held at the Montreal,Museum of Fi...Montreal.,Points to be covered are:, - Items on ...tion Circular - Corporate Presentations, - ...
Other Biology Technology:Edwards Lifesciences to Webcast Annual Stockholders Meeting 2Renovis Stockholders Approve Acquisition by Evotec 2Prometic provides information for its Annual and Special Meeting of Shareholders 2
(Date:11/26/2009)... , Prized for their impressive antlers, red deer ...tions. But a deer,s antlers are much more than dec...together when duelling. John Currey, from The Univ...anical properties of bone for over half a century ...ties of antler through a long-standing collaborati...
(Date:11/26/2009)... , MRSA (methicillin-resistant Staphylococcus Au...e annihilation as low-temperature plasma prototype... easy and unfailing bactericidal cocktails. , Tw...fficient disinfection of healthy skin (e.g. hands ...teria can pose a lethal threat; and another to sho...
(Date:11/25/2009)... , Dr. Sarit Larisch, Head of the Cell Death Re...artment of Biology, has been awarded the prestigio... research exploring the cause of brain cell damage...ed each year to scientists in support of innovatio..., and officially conferred earlier this month at a...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Smoking Bans Reduce Heart Attacks 3A Study 59555 1Smoking Bans Reduce Heart Attacks 3A Study 59555 2Smoking Bans Reduce Heart Attacks 3A Study 59555 3Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 59552 1Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 59552 2Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 59552 3Dr Oz Host of The Dr Oz Show to Accept Honorary CLIO Healthcare Award Live at Nielsens First Ever CLIO Healthcare Awards Mixer 59549 1Dr Oz Host of The Dr Oz Show to Accept Honorary CLIO Healthcare Award Live at Nielsens First Ever CLIO Healthcare Awards Mixer 59549 2Dr Oz Host of The Dr Oz Show to Accept Honorary CLIO Healthcare Award Live at Nielsens First Ever CLIO Healthcare Awards Mixer 59549 3
...Boston, MA Current research suggests that lowerin...ors. The related report by Solomon et al, "Ezetim...s in the March 2009 issue of The American Journal... to atherosclerosis and heart disease, but may als...ostate cancer is the most common non-skin cancer i...
...Madison, WI, February 24, 2009 | Tiny sediment gra...mixture of minerals in an open fabric that results...ween the grains. Scientists at the U.S. Geological... and finding that the mineral composition of these...ne (i.e., between land surface and the water table...
...A Canadian scientist, now based in the UK and fund... Research Council, has harnessed a new drug discov...sulin secretion process. This finding could spark ...abetes. , In work published this week in Nature...f Oxford, led by University of Saskatchewan gradua...
Other Biology News:Lowering your cholesterol may decrease your risk of cancer 2Ultra-fine coatings on sediment grains influence nitrate and sulfate storage in soil 2Canadian scientist mines drugs database for new diabetes treatment 2
Goat Anti-Horse IgG(T) Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Goat Anti-Human STMN2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-RNase L Monoclonal Antibody, Unconjugated, Clone 2E9 from Novus Biologicals
Rabbit Anti-Porcine Vitronectin Antibody, Unconjugated from Cosmo Bio Co., Ltd.
Biology Products: